Allergic inflammation is linked to a higher risk of viral infections, with the study aiming to determine if omalizumab can reduce rhinovirus (RV) illnesses in children with allergic asthma.
In a study involving 478 children, those treated with omalizumab showed decreased duration and frequency of RV infections compared to those receiving standard asthma care.
The results indicate that omalizumab effectively reduces the risk of RV illnesses by targeting IgE, confirming its role in improving outcomes for children with allergic asthma.